AMPLIFY Trial

FDA Approves First All-Oral, Fixed-Duration First-Line CLL/SLL Regimen: Calquence Plus Venetoclax

The ruling rests on AMPLIFY Phase III results showing superior progression-free survival to chemoimmunotherapy.